论文部分内容阅读
目的观察缬沙坦单纯用药和缬沙坦联合氨氯地平治疗高血压左心肥厚的临床效果。方法174例高血压左心肥厚患者,随机分成87例缬沙坦联合氨氯地平治疗的治疗组。87例缬沙坦单纯用药的对照组。监测定两组患者治疗前后收缩压(SBP)、舒张压(DBP)、心率(HR)、舒张期室间隔厚度(IVST)、左心室后壁厚度(LVPWT)、舒张期左室内径(LVDd)、左室重量指数(LVMI)的变化情况。结果治疗组SBP、DBP、HR、IVST、LVPWT、LVDd、LVMI治疗前后有非常显著的差异(P<0.05,P<0.01,P<0.001)。对照组SBP、DBP、IVST、LVPWT、LVDd、LVMI治疗前后也有显著差异(P<0.05,P<0.01,P<0.001),但治疗组SBP、HR、IVST、LVPWT的改善情况优于对照组(P<0.05,P<0.01)。讨论我们的研究表明,缬沙坦联合氨氯地平治疗高血压左心室肥厚的疗效、安全性及耐受性均好,不良反应小,对原发性高血压合并左心室肥厚患者是一种较为理想的治疗方案,但单纯采用缬沙坦治疗高血压左心室肥厚也是一种比较好的方法。
Objective To observe the clinical effect of valsartan alone and valsartan combined with amlodipine in the treatment of left ventricular hypertrophy of hypertension. Methods 174 cases of hypertensive left ventricular hypertrophy were randomly divided into 87 cases of valsartan combined with amlodipine treatment group. 87 cases of valsartan simple drug control group. The systolic blood pressure (SBP), diastolic blood pressure (DBP), heart rate (HR), diastolic interventricular septum thickness (IVST), left ventricular posterior wall thickness (LVPWT) and diastolic left ventricular diameter (LVDd) , Left ventricular mass index (LVMI) changes. Results There were significant differences in SBP, DBP, HR, IVST, LVPWT, LVDd and LVMI before and after treatment in the treatment group (P <0.05, P <0.01, P <0.001). The SBP, DBP, IVST, LVPWT, LVDd and LVMI in the control group were also significantly different before and after treatment (P <0.05, P <0.01, P <0.001) P <0.05, P <0.01). Discussion Our study showed that valsartan combined with amlodipine in the treatment of hypertensive left ventricular hypertrophy efficacy, safety and tolerability are good, with little adverse reactions, hypertension in patients with left ventricular hypertrophy is a relatively Ideal treatment options, but the simple use of valsartan in the treatment of hypertensive left ventricular hypertrophy is also a better method.